Douglas Miehm
Stock Analyst at RBC Capital
(1.04)
# 3,488
Out of 4,829 analysts
48
Total ratings
28.57%
Success rate
-6.2%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $4.78 | +109.42% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $12.09 | +40.61% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.53 | +848.50% | 1 | Mar 10, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $141 → $143 | $106.56 | +34.20% | 5 | Dec 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.16 | -1.96% | 9 | Feb 16, 2024 |
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $4.78
Upside: +109.42%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $12.09
Upside: +40.61%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.53
Upside: +848.50%
Ligand Pharmaceuticals
Dec 11, 2024
Maintains: Outperform
Price Target: $141 → $143
Current: $106.56
Upside: +34.20%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.16
Upside: -1.96%